Moneycontrol PRO
Open App

Buy Dr. Reddy’s Laboratories: target of Rs 5900: Sharekhan

Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5900 in its research report dated December 24, 2021.

December 27, 2021 / 05:21 PM IST
  • bselive
  • nselive
Todays L/H

Sharekhan's research report on Dr. Reddy’s Laboratories

With onset of new Omicron variant of Covid 19, demand for DRL’s Covid drugs including Sputnik vaccines is likely to improve. USFDA’s EUA for Molnupiravir could also likely have a positive rub off as DRL holds rights for Molnupiravir for India and other LMIC’s. DRL is committed to resolving the USFDA observations for Duvvada formulations plant and is confident of submitting timely responses. Strong product pipeline, pick up in base business to drive US sales and enable DRL to tide over competitive pressures while new launches, expanding penetration and pick up in existing portfolio including Covid basket to drive India sales.


We re-iterate Buy recommendation on Dr Reddys Laboratories (DRL) with an unchanged PT of Rs 5900.

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Dec 27, 2021 05:21 pm
ISO 27001 - BSI Assurance Mark